Physician profile
Samuel Shankle
NPI 1053142067
$420.73
in general payments reported to CMS, 2019-2025
14 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $96.34 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65.22 | 2024-2025 | Airsupra, Breztri |
| Nxstage Medical, INC. | $62.07 | 2024 | |
| Inspire Medical Systems, INC. | $57.52 | 2025 | Inspire |
| Novo Nordisk INC | $48.84 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $26.91 | 2025 | Arexvy, Shingrix |
| Dexcom, INC. | $26.59 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $20.12 | 2025 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $20.04 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.00 | 2025 | Caplyta |
| Acella Pharmaceuticals, LLC | $17.15 | 2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $14.77 | 2025 | Rexulti |
| Abbvie INC. | $13.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2025 | Jardiance |
| Lilly USA, LLC | $13.76 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Shankle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.